Vimseltinib is a small molecule commercialized by Ono Pharmaceutical, with a leading Pre-Registration program in Tenosynovial Giant Cell Tumor. According to Globaldata, it is involved in 4 clinical trials, of which 3 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Vimseltinib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Vimseltinib is expected to reach an annual total of $146 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Vimseltinib Overview
Vimseltinib (DCC-3014) is under development for the treatment of advanced malignancies such as solid tumors and tenosynovial giant cell tumor and chronic graft versus host disease. It is administered orally. The drug candidate acts by targeting the FMS kinase (also known as CSF1R). It is developed based on kinase inhibitor technology. It was also under development for the treatment of glioma, renal cell carcinoma and osteolytic cancer.
It was also under development for the treatment of acute myeloid leukemia (AML), colorectal cancer, bone metastasis, prostate cancer, myelodysplastic syndrome (MDS), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL).
Ono Pharmaceutical Overview
Ono Pharmaceutical is an immuno-oncology company that provides research, development, manufacture and sale of prescription pharmaceuticals and diagnostic reagents. Its product portfolio includes medicines for the treatment of type II diabetes, overactive bladder, osteoporosis, cancer, chemotherapy-induced nausea and vomiting, osteoporosis, Alzheimer’s disease, peripheral circulatory disorder, bronchial asthma and allergic rhinitis, among others for the treatment of cancer. The company also offers products in various formulations such as capsules, patches, dry syrup, tablets, injections, and intravenous infusions. Ono Pharmaceutical has manufacturing facilities including Joto Product Development Center, Yamaguchi Plant, and Fujiyama Plant. It offers products in the Americas, Europe, and Asia. Ono Pharmaceutical is headquartered in Osaka, Japan.
The company reported revenues of (Yen) JPY502,672 million for the fiscal year ended March 2024 (FY2024), an increase of 12.4% over FY2023. In FY2024, the company’s operating margin was 31.8%, compared to an operating margin of 31.7% in FY2023. In FY2024, the company recorded a net margin of 25.5%, compared to a net margin of 25.2% in FY2023.
The company reported revenues of JPY117,675 million for the first quarter ended June 2024, an increase of 4.4% over the previous quarter.
For a complete picture of Vimseltinib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
